MARKET

SNDX

SNDX

Syndax
NASDAQ

Real-time Quotes | Nasdaq Last Sale

23.30
-0.28
-1.19%
After Hours: 23.30 0 0.00% 17:22 03/08 EST
OPEN
23.33
PREV CLOSE
23.58
HIGH
24.45
LOW
22.55
VOLUME
1.02M
TURNOVER
--
52 WEEK HIGH
27.85
52 WEEK LOW
6.88
MARKET CAP
1.08B
P/E (TTM)
-12.3745
1D
5D
1M
3M
1Y
5Y
BRIEF-Syndax Pharmaceuticals Reports Q4 Financial Results
reuters.com · 3h ago
8-K: Syndax Pharmaceuticals Inc
(EDGAR Online via COMTEX) -- false 0001395937 0001395937 2021-03-08 2021-03-08 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 4h ago
Syndax Pharmaceuticals: Enrollment Underway in Pivotal Phase 2 AGAVE-201 Trial of Axatilimab in CGVHD >SNDX
Syndax Pharmaceuticals: Enrollment Underway in Pivotal Phase 2 AGAVE-201 Trial of Axatilimab in CGVHD >SNDX
Dow Jones · 4h ago
Syndax Pharmaceuticals: Phase 1 AUGMENT-101 Data Expected in Late 1Q or Early 2Q >SNDX
Syndax Pharmaceuticals: Phase 1 AUGMENT-101 Data Expected in Late 1Q or Early 2Q >SNDX
Dow Jones · 4h ago
Syndax Pharmaceuticals: Phase 2 Expansion Cohorts Expected to Commence in 2Q >SNDX
Syndax Pharmaceuticals: Phase 2 Expansion Cohorts Expected to Commence in 2Q >SNDX
Dow Jones · 4h ago
Syndax Pharmaceuticals 4Q Loss/Shr 44c >SNDX
Syndax Pharmaceuticals 4Q Loss/Shr 44c >SNDX
Dow Jones · 4h ago
Syndax Pharmaceuticals reports Q4 results
Syndax Pharmaceuticals (SNDX): Q4 GAAP EPS of -$0.44 beats by $0.03.Cash, cash equivalents and short-term investments of $293.1M and 51.4M shares and share equivalents issued and outstanding.Shares -1.2% AH.Press Release
Seekingalpha · 4h ago
Syndax Pharmaceuticals Q4 EPS $(0.44) Beats $(0.49) Estimate, Sales $380.00K Beat $200.00K Estimate
Syndax Pharmaceuticals (NASDAQ:SNDX) reported quarterly losses of $(0.44) per share which beat the analyst consensus estimate of $(0.49) by 10.2 percent. This is unchanged from the same period last year. The company
Benzinga · 4h ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SNDX. Analyze the recent business situations of Syndax through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SNDX stock price target is 32.14 with a high estimate of 39.00 and a low estimate of 25.00.
EPS
Institutional Holdings
Institutions: 195
Institutional Holdings: 46.86M
% Owned: 101.05%
Shares Outstanding: 46.37M
TypeInstitutionsShares
Increased
50
13.08M
New
63
2.27M
Decreased
24
3.12M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.04%
Pharmaceuticals & Medical Research
-0.50%
Key Executives
Chairman/Independent Director
Dennis Podlesak
President/Chief Operating Officer/Director
Michael Metzger
Chief Executive Officer/Director
Briggs Morrison
Chief Financial Officer/Chief Accounting Officer/Treasurer
Daphne Karydas
Senior Vice President/General Counsel/Secretary
Luke Albrecht
Senior Vice President
Michael Meyers
Chief Scientific Officer
Peter Ordentlich
Independent Director
Fabrice Egros
Independent Director
Jennifer Jarrett
Independent Director
Keith Katkin
Independent Director
Pierre Legault
Independent Director
William Meury
No Data
About SNDX
Syndax Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The Company’s product candidate, entinostat, is a once-weekly, oral, small molecule, Class I histone deacetylases (HDAC) inhibitor that being evaluated in the Phase III E2112 registrational clinical trial in combination with exemestane for hormone receptor positive, human epidermal growth factor receptor 2 negative, and breast cancer. The Company’s clinical-stage product candidate, SNDX-5613, is the orally available, small molecule inhibitor of the interaction of menin with the mixed lineage leukemia protein (MLL). It is developing SNDX-5613 as a targeted therapy to treat two genetically defined acute leukemias: mixed lineage leukemia-rearranged (MLLr), and acute myeloid leukemia (AML), with a mutated nucleophosmin 1. It is also developing SNDX-6352, a monoclonal antibody targeting the colony stimulating factor-1 receptor.

Webull offers kinds of Syndax Pharmaceuticals Inc stock information, including NASDAQ:SNDX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SNDX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SNDX stock methods without spending real money on the virtual paper trading platform.